Management of Zanubrutinib in the Setting of Bleeding
Zanubrutinib should be held for clinically significant bleeding, with the duration of interruption depending on bleeding severity and surgical context. 1
Bleeding Risk with Zanubrutinib
Zanubrutinib carries a notable hemorrhagic risk, though lower than first-generation BTK inhibitors. Fatal and serious hemorrhage has occurred in patients treated with zanubrutinib, with Grade 3 or higher hemorrhage (including intracranial and gastrointestinal hemorrhage, hematuria, and hemothorax) reported in 3.8% of patients, with fatalities in 0.2%. 1 Bleeding of any grade occurred in 32% of patients, and importantly, bleeding has occurred both with and without concomitant antiplatelet or anticoagulation therapy. 1
Zanubrutinib demonstrates a more favorable bleeding profile compared to ibrutinib, with lower rates of major bleeding events (3.2% vs higher rates with ibrutinib). 2 However, case reports document serious bleeding complications including recurrent hemorrhagic pleural effusion. 3
When to Hold Zanubrutinib
For Active Bleeding
The FDA label provides clear guidance: discontinue zanubrutinib immediately if intracranial hemorrhage of any grade occurs. 1
For other significant bleeding events, the approach mirrors management of oral anticoagulants:
Major bleeding (bleeding at critical sites, hemodynamic instability, or hemoglobin decrease ≥2 g/dL): Stop zanubrutinib immediately and initiate appropriate bleeding control measures. 4
Non-major bleeding: The decision to hold zanubrutinib depends on individual factors including whether the patient requires hospitalization, procedure, or transfusion. 4 If hemostasis has been achieved and no procedure is needed, continuing zanubrutinib may be reasonable, though temporary discontinuation is often advisable until clinical stability is achieved. 4
Perioperative Management
For surgical procedures, zanubrutinib should be held 3-7 days before and after surgery, depending on the type of surgery and bleeding risk. 1 The FDA label specifically states:
- Minor surgical procedures: Hold 3 days before and after 5
- Major surgical procedures: Hold 7 days before and after 5
This recommendation is based on zanubrutinib's mechanism of irreversible BTK inhibition affecting platelet function. 6
Dose Modification Algorithm for Bleeding Events
When zanubrutinib is held for bleeding and the patient stabilizes, the FDA provides a structured dose modification approach for severe or life-threatening non-hematological toxicities (which includes major bleeding): 1
- First occurrence: Interrupt zanubrutinib. Once toxicity resolves to Grade 1 or baseline, resume at full dose (160 mg twice daily or 320 mg once daily)
- Second occurrence: Interrupt zanubrutinib. Once resolved, resume at reduced dose (80 mg twice daily or 160 mg once daily)
- Third occurrence: Interrupt zanubrutinib. Once resolved, resume at 80 mg once daily
- Fourth occurrence: Discontinue zanubrutinib permanently
Special Considerations
Coadministration of zanubrutinib with antiplatelet or anticoagulant medications further increases hemorrhage risk. 1 Monitor patients on these combinations closely for bleeding signs and symptoms. 1
For patients with platelet counts 25,000-50,000/mm³ with significant bleeding, zanubrutinib should be interrupted and managed according to the hematologic toxicity algorithm. 1
The NCCN guidelines for CLL note that BTK inhibitors like zanubrutinib should be considered in the benefit-risk assessment for patients requiring antiplatelet or anticoagulant therapies, and patients should be monitored for signs of bleeding. 7 Concomitant warfarin should be avoided. 5
Common Pitfalls
- Do not routinely continue zanubrutinib through major bleeding events - the drug must be held to allow hemostasis
- Do not assume zanubrutinib can be immediately restarted after bleeding resolution - follow the structured dose modification algorithm
- Do not overlook the perioperative window - inadequate holding periods increase surgical bleeding risk
- Do not forget that bleeding can occur without concurrent anticoagulation - zanubrutinib alone affects platelet function through off-target effects 6